BeOne Medicines (BEIGF) Capital Expenditures (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Capital Expenditures data on file, last reported at $43.2 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $43.2 million, down 27.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $169.1 million (up 744.01% YoY), and the FY2025 annual result was $185.8 million, up 164.3% from the prior year.
• Capital Expenditures retreated to $43.2 million in Q1 2026 per BEIGF's latest filing, from $133.8 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $454.3 million in Q4 2023 and troughed at -$329.9 million in Q4 2024.
• A 5-year average of $62.3 million and a median of $60.0 million in 2025 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 274.33% in 2023 and fell as far as 228.34% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $121.4 million in 2022, then jumped by 274.33% to $454.3 million in 2023, then sank by 172.61% to -$329.9 million in 2024, then surged by 140.56% to $133.8 million in 2025, then slumped by 67.67% to $43.2 million in 2026.
• Business Quant data shows BEIGF's Capital Expenditures at $43.2 million in Q1 2026, $133.8 million in Q4 2025, and -$5.9 million in Q3 2025.